What's new? Log in Free sign up

I-Mab (IMAB)

Company Profile

Company profile

Ticker

IMAB

Exchange

Website

www.i-mabbiopharma.com

CEO

Dr. Xi-Yong Fu M.B.A., Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IMAB stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

I-Mab Announces Portfolio Prioritization of

Current report (foreign)

I-Mab Reports Third Quarter 2024 Results

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

CBC Investment I-Mab Ltd

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

GIC Private Ltd

Zang Jingwu Zhang

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart IMAB financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from I-Mab earnings reports.

Institutional ownership, Q3 2024

IMAB institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	35	43	-18.6%
Opened positions	5	3	+66.7%
Closed positions	13	4	+225.0%
Increased positions	5	5	–
Reduced positions	6	17	-64.7%

13F shares	Current	Prev Q	Change
Total value	18.92 bn	26.01 bn	-27.2%
Total shares	151.11 mm	151.91 mm	-0.5%
Total puts	5.80 k	1.90 k	+205.3%
Total calls	56.40 k	3.00 k	+1780.0%
Total put/call ratio	0.1	0.6	-83.8%

Largest owners	Shares	Value	Change
Fortune Eight Jogging	83.02 mm	$0.00	0.0%
CBC Investment I-Mab	23.37 mm	$0.00	0.0%
Tasly Biopharmaceuticals	13.66 mm	$643.85 mm	0.0%
Genexine	8.49 mm	$538.71 mm	0.0%
Hillhouse Capital Advisors	6.91 mm	$8.57 bn	0.0%
Infini Master Fund	5.00 mm	$0.00	0.0%
Caligan Partners	3.50 mm	$4.34 bn	+3.7%
Jingwu Zhang Zang	3.24 mm	$0.00	0.0%
Boothbay Fund Management	1.42 mm	$1.76 bn	+2.9%
Temasek	566.65 k	$702.65 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Gsa Capital Partners	0.00	-272.19 k	EXIT
Exome Asset Management	0.00	-271.40 k	EXIT
BMO Bank of Montreal	0.00	-244.88 k	EXIT
Garden State Investment Advisory Services	144.00 k	+144.00 k	NEW
Caligan Partners	3.50 mm	+124.54 k	+3.7%
STT State Street	0.00	-102.96 k	EXIT
Two Sigma Advisers	499.30 k	-77.30 k	-13.4%
Two Sigma Investments	408.52 k	-69.92 k	-14.6%
Citadel Advisors	98.39 k	+59.68 k	+154.2%
IVZ Invesco	0.00	-57.93 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

I-Mab Chairman Wei Fu Informs His Intent To Purchase Up To $2M Of Company's American Depository Shares

As the planned purchases are to be executed by Wei Fu via his controlled entity, I-Mab cannot guarantee the number of ADSs to be purchased or the time frame in which the ADSs will be bought in the open market.

I-Mab Highlighted Its Strategic Outlook For 2025 And A Re-prioritization Of Resources, With A Focus On Advancing Its Lead Program, Givastomig Targeting First-line Metastatic Gastric Cancers, With Further Potential In Other Solid Tumors

The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study

HC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $8 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $8 price target.

Press releases

From Benzinga Pro

I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

ROCKVILLE, Md., Feb. 04, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer,

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) ROCKVILLE, Md., Jan. 8, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab Reports Third Quarter 2024 Results

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.